Organisation paid for research Program year 2020 Source: CMS Open Payments

Aviva Research

Neither a doctor nor a teaching hospital

Research payments

$733,112

101 payments

Through program year 2020, Aviva Research is reported as receiving $733,112 in research payments, across 101 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$94,009	14
2019	Research	$639,103	87

Breakdown

Who paid Research payments · program years 2019–2020

Hikma Pharmaceuticals USA $481,169 10 payments
Cipla USA Inc. $127,057 45 payments
Sanofi-Aventis U.S. LLC $45,973 12 payments
GlaxoSmithKline, LLC. $36,162 5 payments
AstraZeneca Pharmaceuticals LP $21,099 2 payments
Bayer HealthCare Pharmaceuticals Inc. $14,871 22 payments
Chiesi USA, Inc. $6,781 5 payments

Studies the money was for Research payments · program years 2019–2020

Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $182,914 1 payment
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $145,025 4 payments
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $105,884 1 payment
A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, 4-Week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 Micro GM Inhalation Powder With Advair Diskus 100/50 Micro GM in Asthma Patients $70,579 7 payments
U-Fs-Mu-As3120 $56,478 38 payments
A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro $36,162 5 payments
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $29,939 1 payment
A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers $28,391 3 payments
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $17,992 1 payment
Bay1002670 Fibroids Efficacy US / CN $14,871 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.